Actively Recruiting
Phase 3 Study of NBI-1117568 to Prevent Symptom Relapse in Adults With Schizophrenia Using Randomized Withdrawal Design
Led by Neurocrine Biosciences · Updated on 2026-09-25
560
Participants Needed
25
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug NBI-1117568 in adults with schizophrenia to determine if it can delay the return of symptoms after a stable response to treatment. This Phase 3, placebo-controlled study focuses on adults between 18 and 65 years old who have already shown improvement with antipsychotic therapy. The trial is designed to assess the safety and effectiveness of NBI-1117568 in preventing relapse. Participants first enter an open-label stabilization period during which all receive NBI-1117568. Following this, they are randomly assigned to continue receiving either NBI-1117568 or a placebo in a double-blind treatment period. Both NBI-1117568 and placebo are given as oral capsules. The study includes a parallel design comparing these two groups. Throughout the study, participants will be closely monitored for relapse of schizophrenia symptoms over approximately 30 weeks. Researchers will measure the time from randomization to relapse as the primary outcome. Safety and tolerability are also assessed during the trial. The total study duration extends until July 2029, with regular evaluations to understand how well participants maintain symptom control.
CONDITIONS
Brief Title
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Research Team
N
Neurocrine Medical Information Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here